SBI actively sources and applies for new streams of funding within its research brief. We aim not only to realise the development of concepts, but to actively promote translation and application through collaborations with industry and other partners.

In order to do this, SBI will create a network of researchers locally that will work with a new network of academic partners and industries globally to deliver value for Ireland and Europe.

3D NEONET

Drug Discovery and Delivery NEtwork for ONcology and Eye Therapeutics

Read More
3TR

3TR: Largest-ever Innovative Medicine Initiative 2 (IMI2) immunology project to improve disease management of non-responders to therapy across seven immune-mediated diseases

Read More
ASSET

Analysing and Striking the Sensitivities of Embryonal Tumours

Read More
BREAST-PREDICT

From population to patient: towards personalised breast cancer medicine

Read More
CASyM

Coordination Action Systems Medicine - Implementation of Systems Medicine across Europe

Read More
COLOSSUS

Advancing a Precision Medicine Paradigm in metastatic Colorectal Cancer: Systems based stratification solutions.

Read More
ERACoSysMed

Systems Medicine to address clinical needs.

Read More
MEL-PLEX

Exploiting MELanoma disease comPLEXity to address European research training needs in translational cancer systems biology and cancer systems medicine

Read More
NanoCommons

The European Nanotechnology Community Informatics Platform: Bridging data and disciplinary gaps for industry and regulators.

Read More
PRIMES

Protein interaction machines in oncogenic EGF receptor signalling

Read More
SmartNanoTox

Smart Tools for Gauging Nano Hazards.

Read More
SynSignal

Synthetic Cellular Signaling Circuits

Read More
SYS-MEL

Systems-based view of melanoma progression: towards novel diagnostic (and therapeutic) applications

Read More
sysVASC

Systems Biology to Identify Molecular Targets for Vascular Disease Treatment

Read More
TOPMed10

Fellowship Programme supporting Career Development and Interdisciplinary Training in Omics driven Personalised Medicine.

Read More
TOP